Provisions under House and Senate versions of prescription drug benefits legislation and their impact on FDA final rules regarding generic drug approvals under the Waxman-Hatch Act.
How PBMs Impede Pharmacists’ Ability to Perform Clinical Services | APhA 2025
March 31st 2025Antonio Ciaccia, President of 3 Axis Advisors, led a discussion on pharmacy benefit manager reform and how the inability to pass legislation has led to increased financial hardships in community pharmacy.